Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...
BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline
France-based BioMérieux is set to acquire the assets of Day Zero Diagnostics, a US-based infectious...
Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...
BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development
Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD...
GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology
US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...
Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC
China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...
AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...
Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute
China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...
Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease
Switzerland-based Roche (SWX: ROG, OTCMKTS: RHHBY) announced its decision to advance prasinezumab, an anti-α-synuclein antibody...
Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...
AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June
Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...
Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion
US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...
Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray
China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...
Minova Pharmaceuticals Launches Rongzhi, China’s First Injectable Adipocytolytic Drug
Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from...
RemeGen Secures 1,827-Day Patent Extension for Telitacicept in China
China-based pharmaceutical firm RemeGen (HKG: 9995) announced that the China National Intellectual Property Administration has...
Fujian Cosunter Gains Ethics Approval for Phase III Study of Neracorvir in CHB Patients
China-based Fujian Cosunter Pharmaceutical Co., Ltd. (SHE: 300436) announced that it has received ethical approval...
CDE Accepts NDA for Ark Bio’s Azstarys, a Priority-Reviewed ADHD Treatment
China’s Center for Drug Evaluation (CDE) has officially accepted the New Drug Application (NDA) for...
Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...
Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the exercise of unilateral termination rights under its...
Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...